A Novel Approach to Improve Detection of Metastatic and Recurrent Prostate Cancer
Produced in collaboration with ZERO – The End of Prostate Cancer.
This patient education program is sponsored by Blue Earth Diagnostics and Telix Pharmaceuticals.
There are many reasons for renewed hope among patients diagnosed with prostate cancer. Over the past few decades, mortality rates have declined, due in part to recent advances in diagnostics and therapeutics. In addition, PSMA (prostate-specific membrane antigen), a key biomarker for advanced prostate cancer, is overexpressed in more than 80% of men with prostate cancer and could be significant in improving the diagnosis, prognosis, and management of patients.
Watch a panel of urology/oncology clinicians and patient advocates discuss the diagnostic and treatment options for patients with prostate cancer. Experts explain the differences between PSMA and prostate-specific antigen (PSA) and review innovative molecular-imaging techniques that have the potential to provide greater accuracy and personalization of treatment. Panelists explore how advanced imaging can be used to determine staging and localization, detect lesions in recurrence, monitor treatment, and stratify risk in metastatic disease.
Topics to be discussed include:
- Metastatic vs recurrent prostate cancer
- The rationale for radiotracers
- Phenotypic vs genotypic biomarkers
- Why does PSMA-expression level matter?
- What does PSMA-positivity mean?
- When to consider advanced imaging
- Locating imaging centers
- Preparations for advanced imaging
PSMA and PSA as Biomarkers
Talking to Your Team about Advanced Imaging
Resources for Advocating and Staying Healthy
Neal Shore, MD, FACS
Director, CPI, Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, South Carolina
Neal Shore, MD, FACS, is the Medical Director for the Carolina Urologic Research Center. He is the Chief Surgical Officer and Head of Urology of Genesis Care, and he practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on many Boards such as the Duke Global Health Institute and Bladder Cancer Advocacy Network. He is a founder for both CUSP Clinical Trials Consortium and DASHKO, large urology practices data registries. Dr. Shore serves as the National Urology Research Director for Genesis Care and is the Co-Chair of AUA International Prostate Cancer Forum. Furthermore, he has served on the AUA Male Health and AUA Data Committees and the Bladder Cancer Advocacy Think Tank.
Thomas Boike MD, MMM
Chief Medical Officer Theranostics
Radiation Oncologist at Michigan Healthcare Professionals
Thomas Boike, MD, MMM, is currently the US Chief Medical Officer for Theranostics within the GenesisCare Network. He has served as the chief resident at the University of Texas Southwestern in Dallas, Texas, and has had academic appointments as Adjunct Assistant Professor at Wayne State University. Before joining GenesisCare, Dr. Boike served as Network Medical Director for the Karmanos Cancer Institute across the state of Michigan, overseeing oncology quality. He has helped further national quality efforts by serving on ASTRO’s APEx Committee and as a radiation oncology practice surveyor for APEx. Dr. Boike has also been active in enrollment to clinical trials and is a member of NCI Prostate Cancer Task Force. He has numerous publications focusing on prostate, breast, and lung cancer.
Shelby Moneer, MS, CHES
Vice President, Patient Programs & Education
ZERO - The End of Prostate Cancer
Shelby has served as ZERO's Vice President of Patient Programs and Education since September of 2020. She leads ZERO's comprehensive suite of patient support and education programs, including support groups, an annual Summit, the development of educational literature, and various patient support programs. She is an experienced educator and health professional and holds a Certified Health Education Specialist (CHES) credential. After earning an advanced degree in health education, she developed educational programs ranging from tobacco cessation to exercise physiology. Before joining ZERO, Shelby was the Director of Education at the Melanoma Research Foundation for ten years, where she exercised her passion for supporting and educating cancer patients.
Interview Participant - Person with prostate cancer
Interview Participant - co-founder, ProstateNetwork.org